Allogene疗法 ALLO 深 沪
等待开盘 03-27 09:30:00 美东时间
2.4108
+0.081
+3.47%
华盛通- 最 高2.50
- 今 开2.28
- 成交量 357.68万股
- 最 低 2.22
- 昨 收 2.33
- 总市值 5.88亿
- 52周最高 2.80
- 市盈率 静 --
- 换手率 1.47%
- 52周最低 0.8621
- 委 比 -52.36%
- 总股本 2.44亿
- 历史最高 55.00
- 量 比 0.57
- 振 幅 12.02%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 太空概念Satellogic单日暴涨38%！日本在线支付商PayPay上市累涨超50%
太空概念Satellogic单日暴涨38%！将于今日举办NASA供应商研讨会；日本在线支付商PayPay隔夜再升21%，上市累涨超50%>>
03-24 18:51
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.
03-23 22:45
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
电话会总结 ｜ Allogene(ALLO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Allogene业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金及投资状况：** - 截至2025年12月31日，现金、现金等价物及投资总额为2.583亿美元 - 2月份从Servier仲裁托管账户收到2,370万美元 - 年初至今通过ATM股权融资工具筹集2,070万美元 **研发费用：** - 第四季度研发费用2,860万美元，其中包含250万美元非现金股权激励费用 - 2025年全年研发费用1.502亿美元，其中包含1,290万美元非现金股权激励费用 **管理费用：** - 第四季度一般管理费用1,380万美元，其中包含
03-16 14:38
Piper Sandler Maintains Overweight on Allogene Therapeutics, Raises Price Target to $8
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and raises the price target from $7 to $8.
03-14 00:24
REFILE-Allogene Therapeutics Q4 net loss narrows
REFILE-Allogene Therapeutics Q4 net loss narrows Corrects March 12 story to fix typographical error in company's name in headline Overview US cell therapy developer reported Q4 net loss of $38.8 million No revenue reported for Q4 as clinical programs advance Outlook Company expects 2026 operating ca
03-13 04:29
Allogene Therapeutics Q4 EPS $(0.17) Beats $(0.22) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 21.66 percent. This is a 39.29 percent increase over losses of $(0.28) per share
03-13 04:03
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Pivotal Phase 2 ALPHA3 trial with Cema-Cel in first-line consolidation for LBCL aims to prevent relapse through MRD-guided treatment, expanding access beyond academic settings. - Phase 1 RESOLUTION trial with ALLO-329 for autoimmune diseases incorporates Dagger® technology to reduce lymphodepletion, with initial data expected in June 2026. - Ended Q4 2025 with $258.3 million in cash, extending cash runway into Q1 2028, supporting discipline...
03-12 20:02
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Allogene Therapeutics Inc. published an update to their financial calendar
Allogene Therapeutics Inc. published an update to their financial calendar Allogene Therapeutics will report fourth quarter and full year 2025 financial results and provide a business update on March 12, 2026, after the close of the market. A live audio webcast and conference call will follow at 2:0
03-02 21:30
